Obstructive Sleep Apnea in a Patient with Pulmonary Thromboembolism

Viswesvaran Balasubramanian, Jagdish C Suri

ABSTRACT

Pulmonary embolism (PE) is a major manifestation of venous thromboembolism (VTE). Obstructive sleep apnea (OSA) leads to hypercoagulable state and may be associated with recurrent PE in the absence of deep vein thrombosis (DVT). Early identification and treatment of OSA may be helpful in reducing the recurrence of PE. Here, we report a case of OSA presenting with isolated PE without DVT with a brief mention of therapeutic implications.

Keywords: Obstructive sleep apnoea, Pulmonary embolism, Pulmonary thromboembolism.

How to cite this article: Balasubramanian V, Suri JC. Obstructive Sleep Apnea in a Patient with Pulmonary Thromboembolism. Indian Sleep Med 2018;13(3):53-56.

Source of support: Nil
Conflict of interest: None

CASE REPORT

A 58-year-old male patient presented with complaints of exertional dyspnea of modified Medical Research Council (MMRC) Grade I for 2 years. Since 2 months, the patient had gradual deterioration and dyspnea progressed to MMRC Grade IV prior to presentation. Patient denied any history of chest pain, cough, hemoptysis, wheeze, snoring, excessive day time sleepiness, fever, loss of weight and appetite. Patient also denied history of trauma, major surgery, prolonged immobilization, malignancy and long-distance travel in sitting posture. He was previously a diagnosed case of coronary artery disease 6 years back and was on regular treatment with antiplatelet drugs. He was a former smoker with 20 pack years of smoking, who had quit smoking 15 years back. He denied alcohol and illicit drug use. He was an ex-army officer by occupation. Prior to presentation to our institute for further evaluation and management, patient was evaluated in regional service hospital. Investigations revealed polycythemia with hemoglobin of 18.9 gm/dL and hematocrit of 55 with other blood counts being normal. Serum erythropoietin was raised, JAK 2 V617F and exon 2 mutations were negative, and bone marrow biopsy was normocellular with trilineage hematopoiesis. Patient had also received two episodes of phlebotomy outside in view of polycythemia. Other biochemical analysis reports and pulmonary function tests were within normal limits.

On presentation to our institute, the patient was afebrile and on examination at rest, pulse rate was 105/minute, respiratory rate 32/minute, blood pressure was 118/70 mm Hg, and peripheral capillary oxygen saturation was 95% on room air. Auscultation revealed bilateral vesicular breath sounds. Arterial blood gas analysis on fraction of inspired oxygen of 0.21 showed respiratory alkalosis with moderate hypoxemia with widened alveolar-arterial (A-aO₂) gradient (pH: 7.47, partial pressure of carbon dioxide 27 mm Hg, partial pressure of oxygen 68 mm Hg, A-aO₂ gradient 45.6). Electrocardiogram showed nonspecific changes. Echo showed no chamber enlargement with systolic ejection fraction of 60%, mild tricuspid regurgitation, and no evidence of right ventricular dysfunction. Screening for DVT with compression ultrasonography, Doppler study of bilateral lower limb veins, bilateral iliac veins and inferior vena cava did not show evidence of thrombosis (Fig. 1). Since the patient had intermediate clinical probability of PE based on modified Wells scoring and revised Geneva scoring, D-dimer levels were determined which were

---

1Senior Resident, 2Consultant and Professor
1,2Department of Pulmonary, Critical Care and Sleep Medicine
Vardhman Mahavir Medical College and Safdarjung Hospital
New Delhi, India

Corresponding Author: Jagdish C Suri, Consultant and Professor, Department of Pulmonary, Critical Care and Sleep Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India, E-mail: docjcsuri@gmail.com

Fig. 1: Doppler ultrasonogram of deep veins of leg and pelvis showing normal filling
raised. Computed tomography (CT) pulmonary angio-
gram done revealed acute pulmonary thromboembolism
involving right and left main pulmonary artery with
extension to right superior lobar branch and left supe-
rior and inferior lobar branches (Fig. 2). Cardiac enzyme
markers Troponin I and B-type natriuretic peptide were
normal. Risk stratification with pulmonary embolism
severity index (PESI) score categorized patient to inter-
mediate–low-risk group and patient was treated conser-
vatively with parenteral anticoagulation. Evaluation for
prothrombotic condition with protein C, protein S, anti-
thrombin, Factor 5 Leiden mutation, and hyperhomocys-
teinemia was negative. Since the etiology was inconclusive
and prior studies had considered OSA as a risk factor for
PE, polysomnography (PSG) was done in the patient.
The PSG showed multiple episodes of apnea, hypopnea,
and respiratory effort-related arousals with significant
nocturnal desaturation, suggesting OSA (Fig. 3). Continu-
ous positive airway pressure (CPAP) titration at 9 cm H$_2$O
abolished all events including snoring. After 10 days of
therapeutic parenteral anticoagulation with enoxaparin,
patient was administered novel anticoagulant, dabigatran
150 mg twice daily along with CPAP support and oxygen
supplementation, and was discharged. Currently, our
patient is on extended anticoagulation and has symptom-
atic improvement without any recurrence.

DISCUSSION

Pulmonary embolism, a major manifestation of VTE, has
an annual incidence of 1 to 2 cases per 1000 person years
and is associated with significant morbidity and mortal-
ity.$^1$ Data from various cross-sectional and longitudinal
studies indicate that OSA may be an independent risk
factor for VTE diseases and both share common risk
factors of advanced age, physical inactivity, and obesity.$^2$
Studies have also observed an increased recurrence of PE
in patients of OSA and for every 10-unit rise in apnea–
hypopnea index, the risk of PE increases by 45%.$^3$ This is
of major concern due to the high prevalence of OSA and
high morbidity and mortality associated with PE.

It is observed that patients with OSA have hyper-
coagulable state characterized by elevated platelet
activity, fibrinogen levels, plasminogen activator inhibi-
tor-1 levels, polycythemia, erythrocyte adhesiveness,
and aggregation.$^{4,6}$ Vascular endothelial injury due to
recurrent hypoxia and reoxygenation and venous stasis
due to physical inactivity and secondary polycythemia
in OSA promote VTE.$^7$ In the present case, the patient
had normal body mass index and no other identifiable
risk factors of trauma, major surgery, prolonged immo-
bilization, varicose vein, malignancy, obesity, chronic
obstructive lung disease, long-distance travel in sitting

Fig. 2: The CT pulmonary angiogram showing evidence of embolism in bilateral pulmonary artery (arrowheads)

Fig. 3: Epoch from PSG showing findings of OSA
Obstructive Sleep Apnea in a Patient with Pulmonary Thromboembolism

posture. We also excluded other hypercoagulability causes of unprovoked PE like deficiency of protein C, protein S, antithrombin 3, Factor 5 Leiden mutation and hyperhomocysteinemia, suggesting that OSA could be the etiology of PE in our patient. The polycythemia in this patient can be attributed to nocturnal hypoxemia due to OSA and this may have promoted venous stasis. De novo formation of clots within the pulmonary artery or in situ thrombosis due to localized inflammation, endothelial cell damage in OSA may be the reason for the presence of isolated PE in the absence of DVT in our patient. This presentation deserves mention, as these patients would likely not benefit from vena caval filters in case of recurrence.

In accordance with the 2014 guidelines of PE, “advanced” risk assessment PESI score was done. Patient was in intermediate–low-risk group as the RV function was normal on echocardiography and CT angiography, and the patient had normal cardiac biomarker levels. The CPAP was observed to reduce apnea-hypopnea index, hypercoagulation, clot strength and clotting index in patients with concomitant sleep apnea and VTE. However, the contribution of CPAP in secondary prophylaxis of thrombotic events is uncertain. In the present case, patient was hospitalized and received parenteral anticoagulation for 10 days followed by oral dabigatran as extended secondary prophylaxis was deemed. Patient was also initiated on CPAP at 9 cm H₂O to eliminate all obstructive events.

The OSA increases the risk of recurrent PE and other thromboembolic events. Studies have observed that an elevated D-dimer level after stopping anticoagulation is associated with a higher recurrence rate; however, the utility of serial monitoring and re-initiation of anticoagulation remains debatable. Addition of sleep indices like apnea–hypopnea index, mean nocturnal oxygen saturation (SaO₂), and the percentage of total time study spent with SaO₂ < 90% to disabilities of the arm shoulder and Hand symptom score, and Vienna prediction model may improve risk assessment of recurrent PE.

Current guidelines recommend at least 3 months of treatment after initiation of warfarin/novel anticoagulant for PE and DVT. The aim of continuing anticoagulation beyond 6 months is to prevent recurrent thrombosis (prophylaxis). Though it is believed that extended anticoagulation beyond 6 months is required in these patients, there are no randomized controlled trials to verify if these patients can really benefit from prolonged duration anticoagulant treatment. Currently, our patient is on extended anticoagulation and has symptomatic improvement without any recurrence. Such patients should be followed up regularly, as these patients may have recurrence or may progress to chronic thrombopulmonary embolism.

CONCLUSION

The OSA should be evaluated for all patients with unidentifiable cause of PE and in recurrent PE. These patients should be treated with adequate positive airway pressure therapy and prolonged duration of anticoagulation.

REFERENCES

1. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008 Sep;29(18):2276-2315.

2. Durán J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med 2001 Mar;163(3 Pt 1):685-689.

3. Alonso-Fernández A, de la Peña M, Romero D, Piérola J, Herrera M, Barceló A, Soriano JB, García Suquia A, Fernández-Capitán C, Lorenzo A, et al. Association between obstructive sleep apnea and pulmonary embolism. Mayo Clin Proc 2013 Jun;88(6):579-587.

4. Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Oda N, Tanaka A, Yamamoto M, Ohta S, O’Donnell CP, Adachi M. Silent brain infarction and platelet activation in obstructive sleep apnea. Am J Respir Crit Care Med 2007 Mar 15;175(6):612-617.

5. Yardim-Akaydin S, Caliskan-Can E, Firat H, Ardic S, Simsek B. Influence of gender on C-reactive protein, fibrinogen, and erythrocyte sedimentation rate in obstructive sleep apnea. Antinfiamm Antiallergy Agents Med Chem 2014 Mar;13(1):56-63.

6. Peled N, Kassirer M, Kramer MR, Rogowski O, Shlomi D, Fox B, Berliner AS, Shitrit D. Increased erythrocyte adhesiveness and aggregation in obstructive sleep apnea syndrome. Thromb Res 2008;121(5):631-636.

7. Quan SF, O’Connor GT, Quan JS, Redline S, Resnick HE, Shahar E, Siscovick D, Sherrill DL. Association of physical activity with sleep-disordered breathing, Sleep Breath 2007 Sep;11(3):149-157.

8. Corbett V, Hassouna H, Girgis R. In situ thrombosis of the pulmonary arteries: an emerging new perspective on pulmonary embolism. Med Stud Res J 2015;4(Winter):54-58.

9. Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman MV, Humbert M, Kucher N, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014 Nov;35(43):3033-3073.

10. Toukh M, Pereira EJ, Falcon BJ, Liak C, Lerner M, Hopman WM, Iscoe S, Fitzpatrick MF, Othman M. CPAP reduces hyper-

Indian Journal of Sleep Medicine, July-September 2018;13(3):53-56
coagulability, as assessed by thromboelastography, in severe obstructive sleep apnoea. Respir Physiol Neurobiol 2012 Sep 30;183(3):218-223.

11. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Weltermann A, Wagner O, Kyrle PA. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003 Aug 27;290(8):1071-1074.

12. Tosetto A, Iorio A, Marcucci M, Baglin T, Cushn M, Eichinger S, Palareti G, Poli D, Tait RC, Douketis J. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012 Jun;10(6):1019-1025.

13. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010 Apr 13;121(14):1630-1636.

14. Xie J, Wei YX, Liu S, Zhang W, Zhang XF, Li J. Obstructive sleep apnea hypopnea syndrome as a reason for active management of pulmonary embolism. Chin Med J (Engl) 2015 Aug 20;128(16):2147-2153.